Health Care·Biotechnology·$28.6B
Revolution Medicines (RVMD) is a biotechnology company focused on developing targeted therapies for cancer. With a market cap of $29 billion, it operates in the healthcare sector, aiming to address significant unmet medical needs in oncology.
EPS
Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
Revenue figures will provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
13%
Avg EPS Surprise
-8.59%
Avg Stock Reaction
-0.66%
In Q4 2025, Revolution Medicines reported an EPS of $-1.86, missing expectations. The stock reacted negatively, declining 1.52% the following day.
Management Promises & Guidance
Analysts expect Revolution Medicines to report a loss this quarter, with a consensus EPS of $-1.84 and minimal revenue. The market is cautious given the company's recent performance.
Bull Case
If the company can exceed EPS expectations and show stronger revenue, it may indicate progress in its drug development pipeline, boosting investor confidence.
Bear Case
A larger-than-expected loss or disappointing revenue could raise concerns about the company's financial stability and future growth prospects.
EPS
$-1.84Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$2MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will the EPS come in better than the consensus estimate of $-1.84?
A better-than-expected EPS could signal improved operational efficiency or successful drug development, which is crucial for investor confidence.
Q2
What revenue figures will be reported, especially in relation to the $2M consensus?
Revenue performance will be a key indicator of market demand for their products and overall business health.
Why consensus could be wrong
The Street may underestimate the potential for Revolution Medicines to improve its EPS significantly due to recent advancements in its drug pipeline.
Supporting Evidence
The company's focus on targeted therapies could yield better-than-expected results if recent trials show promise.
Historical trends indicate that the market may overreact to short-term misses, providing a buying opportunity.
The lack of recent insider activity suggests management confidence in upcoming developments.
Key Risk
If the EPS comes in better than $-1.70, it could shift the narrative around the company's growth potential.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it reflects the company's ability to manage costs while progressing in its drug development pipeline.
Bull Confirmed If
An EPS of $-1.70 or better, along with revenue exceeding $5M, would confirm a positive outlook.
Bear Confirmed If
An EPS worse than $-1.90 and revenue below $1M would confirm a negative outlook.
Implied Move
±4.2%
There is no options market data available, but the implied move suggests the market is anticipating some volatility around the earnings announcement.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Revolution Medicines beats expectations, history suggests the stock could rise by around 2.31%, confirming a positive outlook.
In-Line / Cautious
If results are in line with expectations, the stock may see muted movement as investors digest the implications of the report.
Miss
A miss on earnings could lead to a decline of about 0.54%, reflecting ongoing concerns about the company's financial health.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026